Search - tctmd.com

Displaying 481 - 500 of 707

Sort: Relevancy | Date

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Bulimia May Contribute to Premature CVD in Women

L.A. McKeown

October 18, 2019

News Daily News

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

Caitlin E. Cox

October 02, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Daily News

Infection During CV Hospital Stays Tied to Higher Costs, Greater Death Risk

Marcus A. Banks

July 24, 2019

News Industry News

Nanowear Announces Clinical Launch of NanoSENSE, a Heart Failure Management and Alert Diagnostic Validation Study

July 22, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

Advertisement

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Bulimia May Contribute to Premature CVD in Women

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Infection During CV Hospital Stays Tied to Higher Costs, Greater Death Risk

Nanowear Announces Clinical Launch of NanoSENSE, a Heart Failure Management and Alert Diagnostic Validation Study

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content